
Dr. Muzammil Shaikh is a senior Medical Oncologist serving as Senior Director – Medical Oncology at Nanavati Max Super Speciality Hospital, Mumbai. With more than 20 years of experience, he specialises in the diagnosis and treatment of different malignancies through chemotherapy, targeted therapy, immunotherapy and precision-based cancer care.
He completed his MBBS from Grant Medical College and Sir J.J. Hospital, Mumbai, in 2001, followed by an MD in Internal Medicine from Seth G.S. Medical College and KEM Hospital in 2006. He subsequently obtained a DM in Medical Oncology from Gujarat Cancer and Research Institute in 2010 and a DNB in Medical Oncology in 2011.
His clinical expertise includes breast cancer, ovarian cancer, lung cancer, gastrointestinal malignancies, hepatobiliary cancers, bone cancers and genitourinary cancers. He also specialises in molecular oncology, cancer genetics, germ cell tumours, neuro-oncology and supportive cancer care.
Before his current association with Nanavati Max, Dr. Shaikh worked at P.D. Hinduja National Hospital and Gujarat Cancer and Research Institute. He also completed an observership at MD Anderson Cancer Center, Houston, United States, and has contributed to medical research and oncology publications.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Muzammil Shaikh for Medical Oncology treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Medical Oncology in India.
Dr. Muzammil Shaikh regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Muzammil Shaikh holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in DM (Medical Oncology)
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
Targeted therapy, immunotherapy, and chemotherapy tailored to molecular profile for all stages.
Hormone therapy, HER2-targeted agents, chemotherapy, and CDK4/6 inhibitors across all subtypes.
Chemotherapy, targeted biologics (bevacizumab, cetuximab), and immunotherapy for GI malignancies.
Platinum-based chemotherapy, EGFR inhibitors, and PD-L1 checkpoint inhibitors.
R-CHOP, R-DHAP, ABVD, and checkpoint inhibitors for all histological subtypes.
Induction chemotherapy, targeted kinase inhibitors, and novel agent combinations for haematological malignancies.
Platinum/taxane-based regimens, PARP inhibitors (BRCA-mutated), and bevacizumab for ovarian and cervical cancers.
Immunotherapy (checkpoint inhibitors), targeted therapy, and hormonal agents for kidney, bladder, and prostate cancers.
Anthracycline-based first-line chemotherapy and trabectedin for advanced sarcomas.
Evidence-based systemic chemotherapy regimens delivered safely with meticulous toxicity management.
Precision oncology using small molecule inhibitors and monoclonal antibodies matched to tumour biology.
PD-1, PD-L1, and CTLA-4 inhibitors harnessing the immune system to fight cancer.
Comprehensive biomarker profiling to match each patient to the most effective treatment.
Endocrine manipulation and DNA-damage repair inhibitors for hormone-receptor-positive and BRCA-mutated cancers.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.